Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany

Felicitas Kühne, Katharina Achtert, Franziska Püschner, Dominika Urbanski-Rini, Juliane Schiller, Ernestine Mahar, Josephine Friedrich, Mark Atwood, Ralf Sprenger, Jeffrey Vietri, Christof von Eiff, Christian Theilacker
doi: https://doi.org/10.1101/2023.02.16.23286052

Article Information

doi 
https://doi.org/10.1101/2023.02.16.23286052
History 
  • June 19, 2023.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Felicitas Kühne1,*,
  2. Katharina Achtert2,
  3. Franziska Püschner2,
  4. Dominika Urbanski-Rini2,
  5. Juliane Schiller2,
  6. Ernestine Mahar1,
  7. Josephine Friedrich1,
  8. Mark Atwood3,
  9. Ralf Sprenger1,
  10. Jeffrey Vietri4,
  11. Christof von Eiff1 and
  12. Christian Theilacker4
  1. 1Pfizer Pharma GmbH, Berlin, Germany
  2. 2Private Institute for Applied Health Services Research (inav), Berlin, Germany
  3. 3Policy Analysis Inc, Boston, Massachusetts, United States of America
  4. 4Pfizer Inc., Collegeville, Pennsylvania, United States of America
  1. ↵*Correspondence to: Felicitas Kühne Pfizer Pharma GmbH Linkstr. 10 10785 Berlin Felicitas.Kuehne{at}pfizer.com +49 (0) 160 1684602
Back to top
Posted June 19, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany
Felicitas Kühne, Katharina Achtert, Franziska Püschner, Dominika Urbanski-Rini, Juliane Schiller, Ernestine Mahar, Josephine Friedrich, Mark Atwood, Ralf Sprenger, Jeffrey Vietri, Christof von Eiff, Christian Theilacker
medRxiv 2023.02.16.23286052; doi: https://doi.org/10.1101/2023.02.16.23286052
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area